US · Healthcare · Biotechnology
EPS came in at -1.15 against a street estimate of -1.06 — a miss of 8.5%.
Analysts rate Crispr Therapeutics AG a buy (13 buy, 10 hold, 0 sell out of 23) with an average price target of $85.63.
| Fund | Stake |
|---|---|
| ARK Investment Management LLC | 9.78% |
| BlackRock Inc | 8.63% |
| Orbis Allan Gray Ltd | 5.64% |
| Capital World Investors | 4.91% |
| State Street Corp | 4.47% |
| GSK PLC | 3.33% |
| Geode Capital Management, LLC | 2.60% |
| T. Rowe Price Investment Management,Inc. | 2.12% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the nine months ended September 30, 2026, total revenue was $24,308, compared with $2,646 in the same period of 2025. • Net l | 2026-11-02 |
| Results announced · Q4 2026 HEADLINE NUMBERS • CASGEVY revenue was $99 million in Q3 2026, up 30% quarter-over-quarter and nearly six times Q3 2025 revenue. • More than 750 pa | 2026-11-02 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer, effective October 19, 2026. • Mr. Silver will also ser | 2026-10-19 |
| Quarterly report · Q2 2026 CRISPR THERAPEUTICS AG - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and marketable securities: $2,364.4 million (June 30, 2026) vs. $1,975.8 mil | 2026-08-03 |
| Results announced · Q3 2026 CRISPR THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • CASGEVY Revenue: $76 million in Q2 2026, up 78% quarter-over-quarter and 151% year- | 2026-08-03 |
| Board / officer change · Q2 2026 CRISPR THERAPEUTICS AG – 8-K SUMMARY HEADLINE NUMBERS • Annual General Meeting held June 4, 2026 • 70,716,663 votes FOR approval of 2025 financial s | 2026-06-04 |
| Quarterly report · Q1 2026 CRISPR THERAPEUTICS AG – FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: $2,441.8 mi | 2026-05-04 |
| Results announced · Q2 2026 CRISPR THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $2,441.8 million in cash, cash equivalents, and marketable s | 2026-05-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Crispr Therapeutics AG — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.